Overview

  • Product nameAnti-Bcl-2 antibody
    See all Bcl-2 primary antibodies
  • Description
    Rabbit polyclonal to Bcl-2
  • SpecificityThis antibody is specific for Bcl2.
  • Tested applicationsSuitable for: WB, ELISA, ICC/IF, IHC-Pmore details
  • Species reactivity
    Reacts with: Human
  • Immunogen

    Synthetic peptide corresponding to Human Bcl-2.
    Database link: P10415

  • Positive control
    • WB: Extracts from MCF7 cells IHC: Breast carcinoma tissue

Associated products

Applications

Our Abpromise guarantee covers the use of ab47489 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
WB Use at an assay dependent concentration. Detects a band of approximately 26 kDa (predicted molecular weight: 26 kDa).
ELISA 1/10000.
ICC/IF Use a concentration of 1 - 5 µg/ml.
IHC-P Use at an assay dependent concentration.

Target

  • FunctionSuppresses apoptosis in a variety of cell systems including factor-dependent lymphohematopoietic and neural cells. Regulates cell death by controlling the mitochondrial membrane permeability. Appears to function in a feedback loop system with caspases. Inhibits caspase activity either by preventing the release of cytochrome c from the mitochondria and/or by binding to the apoptosis-activating factor (APAF-1). May attenuate inflammation by impairing NLRP1-inflammasome activation, hence CASP1 activation and IL1B release (PubMed:17418785).
  • Tissue specificityExpressed in a variety of tissues.
  • Involvement in diseaseA chromosomal aberration involving BCL2 has been found in chronic lymphatic leukemia. Translocation t(14;18)(q32;q21) with immunoglobulin gene regions. BCL2 mutations found in non-Hodgkin lymphomas carrying the chromosomal translocation could be attributed to the Ig somatic hypermutation mechanism resulting in nucleotide transitions.
  • Sequence similaritiesBelongs to the Bcl-2 family.
  • DomainBH1 and BH2 domains are required for the interaction with BAX and for anti-apoptotic activity.
    The BH4 motif is required for anti-apoptotic activity and for interaction with RAF1 and EGLN3.
    The loop between motifs BH4 and BH3 is required for the interaction with NLRP1.
  • Post-translational
    modifications
    Phosphorylation/dephosphorylation on Ser-70 regulates anti-apoptotic activity. Growth factor-stimulated phosphorylation on Ser-70 by PKC is required for the anti-apoptosis activity and occurs during the G2/M phase of the cell cycle. In the absence of growth factors, BCL2 appears to be phosphorylated by other protein kinases such as ERKs and stress-activated kinases. Phosphorylated by MAPK8/JNK1 at Thr-69, Ser-70 and Ser-87, wich stimulates starvation-induced autophagy. Dephosphorylated by protein phosphatase 2A (PP2A).
    Proteolytically cleaved by caspases during apoptosis. The cleaved protein, lacking the BH4 motif, has pro-apoptotic activity, causes the release of cytochrome c into the cytosol promoting further caspase activity.
    Monoubiquitinated by PARK2, leading to increase its stability. Ubiquitinated by SCF(FBXO10), leading to its degradation by the proteasome.
  • Cellular localizationMitochondrion outer membrane. Nucleus membrane. Endoplasmic reticulum membrane.
  • Information by UniProt
  • Database links
  • Alternative names
    • Apoptosis regulator Bcl 2 antibody
    • Apoptosis regulator Bcl-2 antibody
    • Apoptosis regulator Bcl2 antibody
    • AW986256 antibody
    • B cell CLL/lymphoma 2 antibody
    • B cell leukemia/lymphoma 2 antibody
    • Bcl-2 antibody
    • Bcl2 antibody
    • BCL2_HUMAN antibody
    • C430015F12Rik antibody
    • D630044D05Rik antibody
    • D830018M01Rik antibody
    • Leukemia/lymphoma, B-cell, 2 antibody
    • Oncogene B-cell leukemia 2 antibody
    • PPP1R50 antibody
    • Protein phosphatase 1, regulatory subunit 50 antibody
    see all

Anti-Bcl-2 antibody images

  • All lanes : Anti-Bcl-2 antibody (ab47489) at 1/500 dilution

    Lane 1 : Extracts from MCF7 cells treated with etoposide
    Lane 2 : Extracts from MCF7 cells treated with etoposide with synthesized peptide at 1 µg/ml

    Lysates/proteins at 30 µg per lane.

    Secondary
    Alkaline Phosphatase AffiniPure Goat Anti-Rabbit IgG (H+L)

    Predicted band size : 26 kDa
    Observed band size : 26 kDa
  • Immunohistochemical analysis of paraffin-embedded breast carcinoma, using ab47489 at a 1/50 dilution.
    Left image: Untreated
    Right image: Treated with synthesized peptide
    Immunohistochemical analysis of paraffin-embedded breast carcinoma, using ab47489 at a 1/50 dilution.
    Left image: Untreated
    Right image: Treated with synthesized peptide
  • ICC/IF image of ab47489 stained HeLa cells. The cells were 4% PFA fixed (10 min) and then incubated in 1%BSA / 10% normal goat serum / 0.3M glycine in 0.1% PBS-Tween for 1h to permeabilise the cells and block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab47489, 1µg/ml) overnight at +4°C. The secondary antibody (green) was Alexa Fluor® 488 goat anti-rabbit IgG (H+L) used at a 1/1000 dilution for 1h. Alexa Fluor® 594 WGA was used to label plasma membranes (red) at a 1/200 dilution for 1h. DAPI was used to stain the cell nuclei (blue) at a concentration of 1.43µM.

  • ab47489 staining BCL2 in MCF7 cells treated with ICI 182,780 (ab120131), by ICC/IF. Decrease in BCL2 expression correlates with increased concentration of ICI 182,780 as described in literature.
    The cells were incubated at 37°C for 3h in media containing different concentrations of ab120131 (ICI 182,780) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab47489 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A goat anti-rabbit DyLight 488 polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.

  • ab47489 staining Bcl-2 MCF7 cells treated with diadzein (ab120391), by ICC/IF. Decrease in Bcl2 expression correlates with increased concentration of diadzein, as described in literature.
    The cells were incubated at 37°C for 6h in media containing different concentrations of ab120391 (diadzein) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab47489 (5 µg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A goat anti-rabbit DyLight 488 polyclonal antibody (ab96899) at 1/250 dilution was used as the secondary antibody.

References for Anti-Bcl-2 antibody (ab47489)

This product has been referenced in:
  • Loughran ST  et al. Bfl-1 is a crucial pro-survival nuclear factor-?B target gene in Hodgkin/Reed-Sternberg cells. Int J Cancer 129:2787-96 (2011). Read more (PubMed: 21491422) »

See 1 Publication for this product

Product Wall

There are currently no Abreviews or Questions for ab47489.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"